|1.||Bradner, James E: 3 articles (08/2011 - 09/2008)|
|2.||Mazitschek, Ralph: 2 articles (08/2011 - 06/2009)|
|3.||Rodriguez-Gonzalez, Agustin: 2 articles (08/2011 - 07/2008)|
|4.||Lin, Tara: 2 articles (08/2011 - 07/2008)|
|5.||Sakamoto, Kathleen M: 2 articles (08/2011 - 07/2008)|
|6.||Ikeda, Alan K: 2 articles (08/2011 - 07/2008)|
|7.||Howard, Brynn N: 1 article (03/2014)|
|8.||Habringer, Stefan: 1 article (03/2014)|
|9.||Gradilone, Sergio A: 1 article (03/2014)|
|10.||Masyuk, Tatyana V: 1 article (03/2014)|
|1.||Urinary Bladder Neoplasms (Bladder Cancer)
08/01/2011 - "Furthermore, the signaling pathways activated by tubacin appear to be distinct from those observed in multiple myeloma. "
07/01/2008 - "Tubacin acts synergistically with the proteasome inhibitor, bortezomib, to induce cytotoxicity in one type of hematologic malignancy, multiple myeloma. "
|3.||Burkitt Lymphoma (Burkitt's Lymphoma)
06/19/2009 - "We found that Epstein-Barr virus (EBV)-positive Burkitt lymphoma (BL) cells were generally killed by lower doses of tubacin than EBV-transformed lymphoblastoid cells (LCLs) or EBV-negative BL cells. "
06/19/2009 - "Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis."
01/01/2014 - "Burkitt's lymphoma cells were pharmacologically treated with niltubacin, tubacin or sodium butyrate (NaB) or transfected with siRNAs to knock down the expression of HDAC6. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|5.||Hematologic Neoplasms (Hematological Malignancy)
|1.||Proteasome Endopeptidase Complex (Proteasome)
|2.||Reactive Oxygen Species (Oxygen Radicals)